Crunching the numbers for CGEM... Refresh in a moment for the full analysis.
Cullinan Therapeutics, Inc. (CGEM)
mixed
$14.54
Updated: 2026-04-13
51
TradeApes Score
hold
Financial Strength
60
Healthy
Operating Trend
30
Weak
Valuation
50
Mixed
Capital Allocation
50
Mixed
Risk
80
Strong
Key Findings
+
Low leverage — net debt/EBITDA below 1×
−
FCF deteriorating — free cash flow down more than 25% year over year
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Add to Watchlist
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.